$0.74
3.17% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US74345W1080
Symbol
PRPH

ProPhase Labs, Inc. Stock price

$0.74
-1.65 68.85% 1M
-4.31 85.26% 6M
-3.78 83.53% YTD
-3.84 83.74% 1Y
-4.62 86.13% 3Y
-0.81 52.13% 5Y
-0.06 7.34% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.02 3.17%
ISIN
US74345W1080
Symbol
PRPH

Key metrics

Market capitalization $17.77m
Enterprise Value $46.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.63
P/S ratio (TTM) P/S ratio 1.39
P/B ratio (TTM) P/B ratio 0.37
Revenue growth (TTM) Revenue growth -79.66%
Revenue (TTM) Revenue $12.75m
EBIT (operating result TTM) EBIT $-35.41m
Free Cash Flow (TTM) Free Cash Flow $-16.63m
Cash position $1.10m
EPS (TTM) EPS $-1.50
P/E forward 0.95
P/S forward 1.20
EV/Sales forward 3.13
Short interest 0.97%
Show more

Is ProPhase Labs, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

ProPhase Labs, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast ProPhase Labs, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast ProPhase Labs, Inc.:

Buy
100%

Financial data from ProPhase Labs, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
13 13
80% 80%
100%
- Direct Costs 17 17
47% 47%
132%
-4.13 -4.13
114% 114%
-32%
- Selling and Administrative Expenses 23 23
42% 42%
177%
- Research and Development Expense 0.81 0.81
50% 50%
6%
-27 -27
187% 187%
-215%
- Depreciation and Amortization 7.97 7.97
38% 38%
63%
EBIT (Operating Income) EBIT -35 -35
131% 131%
-278%
Net Profit -28 -28
165% 165%
-218%

In millions USD.

Don't miss a Thing! We will send you all news about ProPhase Labs, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ProPhase Labs, Inc. Stock News

Neutral
Seeking Alpha
11 days ago
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2024 Results Conference Call November 13, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications.
Neutral
GlobeNewsWire
15 days ago
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results wi...
Neutral
GlobeNewsWire
18 days ago
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approxim...
More ProPhase Labs, Inc. News

Company Profile

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer consumer healthcare products and dietary supplements. Its products include TK supplement. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Doylestown, PA.

Head office United States
CEO Ted Karkus
Employees 113
Founded 1989
Website www.prophaselabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today